Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech IPOs: Why Values Will Increase

This article was originally published in Start Up

Executive Summary

Acquisitions and crossover investors are just beginning to push up IPO prices for the best biotech offerings, providing the first hints of real competition for shares of new issues.

You may also be interested in...



Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007

In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for July-September 2007. Our data come from Windhover's Strategic Transactions Database.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007

In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for July-September 2007. Our data come from Windhover's Strategic Transactions Database.

Therapeutic Area Partnerships: Faster, Earlier and Make Mine Cash

The rising dealmaking value of proof of concept (POC) was the key theme at Windhover's Therapeutic Area Partnerships meeting, (Oct. 24-26, 2007). In 2002 and 2003 companies paid roughly three times the value for Phase III products that they paid for Phase II. Now, candidates at Phase II (a proxy for POC) go for about the same price as Phase III drugs. What’s going on here and what role will Big Pharma and mid-size companies find themselves playing if the trend continues?

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS141439

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel